  |
|
 |
|
Case Report
| ||||||
| SGLT2 inhibitor associated diabetic ketoacidosis | ||||||
| Evdoxia Mitsiou1, Charalampos Mandros2, Kalliopi Kotsa3, Frangiskos Koulis1, Charalampos Christofidis1, Sofia Georgiadi1, Theodolinta Testa1, Alexandros Anastasiou1, Evgenia Efthymiou1, Evangelos Potolidis1 | ||||||
|
1MD, 2nd, Department of Internal Medicine, General Hospital of Volos, Polimeri 134, 38222 Volos, Greece.
2MD, PhD, 2nd Department of Internal Medicine, General Hospital of Volos, Polimeri 134,38222 Volos, Greece. 3MD, PhD, Associate Professor of Endocrinology and Diabetology, University Hospital of Ahepa, Aristotle University of Thessaloniki, Kiriakidi 1,54636 Thessaloniki, Greece. | ||||||
| ||||||
|
[HTML Full Text]
[PDF Full Text]
[Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar] 
|
| How to cite this article |
| Mitsiou E, Mandros C, Kotsa K, Koulis F, Christofidis C, Georgiadi S, Testa T, Anastasiou A, Efthymiou E, Potolidis E. SGLT2 inhibitor associated diabetic ketoacidosis. Int J Case Rep Images 2017;8(4):239–241. |
|
Abstract
|
|
Empagliflozin is a representative of SGLT2 inhibitors, which is used for the treatment of type 2 diabetes mellitus. Common adverse reactions are hypoglycemia and urinary tract infections. We reported a case of 76-year-old female, receiving empagliflozin and being admitted to the hospital because of diabetic ketoacidosis.
| |
|
Keywords:
Diabetes type 2, Empagliflozin, Ketoacidosis
| |
|
[HTML Full Text]
[PDF Full Text]
|
|
Author Contributions
Evdoxia Mitsiou – Substantial contributions to conception and design, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Charalampos Mandros – Substantial contributions to conception and design, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Kalliopi Kotsa – Substantial contributions to conception and design, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Frangiskos Koulis – Substantial contributions to conception and design, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Charalampos Christofidis – Substantial contributions to conception and design, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Sofia Georgiadi – Substantial contributions to conception and design, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Theodolinta Testa – Substantial contributions to conception and design, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Alexandros Anastasiou – Substantial contributions to conception and design, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Evgenia Efthymiou – Substantial contributions to conception and design, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published Evangelos Potolidis – Substantial contributions to conception and design, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published |
|
Guarantor of submission
The corresponding author is the guarantor of submission. |
|
Source of support
None |
|
Conflict of interest
Authors declare no conflict of interest. |
|
Copyright
© 2017 Evdoxia Mitsiou et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information. |
|
|